Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

Vaccine

Volumn 31, Issue 43, 2013, Pages 4968-4974

  Frosi, Giacomo ^a,c   Biolchi, Alessia ^a   Sapio, Morena Lo ^a,d   Rigat, Fabio ^a   Gilchrist, Stefanie ^b   Lucidarme, Jay ^b   Findlow, Jamie ^b   Borrow, Ray ^b   Pizza, Mariagrazia ^a   Giuliani, Marzia Monica ^a   Medini, Duccio ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Local Health Service   (Italy)

Author keywords

4CMenB vaccine strain coverage; MATS; Neisseria meningitidis serogroup B; Serum bactericidal antibody assay; Stratified proportional sampling

Indexed keywords

MENINGOCOCCUS VACCINE;

ACCURACY; ADOLESCENT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; MENINGOCOCCOSIS; METHODOLOGY; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP B; NONHUMAN; PHENOTYPE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SAMPLING; SEROLOGY; SERUM; SERUM BACTERICIDAL ANTIBODY ASSAY; STRATIFIED PROPORTIONAL SAMPLING; UNITED KINGDOM; VACCINATION; VACCINE STRAIN COVERAGE;

4CMENB VACCINE STRAIN COVERAGE; CAPSULAR GROUP B MENINGOCOCCUS; CC; CLONAL COMPLEX; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR H BINDING PROTEIN; FALSE NEGATIVES; FALSE POSITIVES; FHBP; FN; FP; HEALTH PROTECTION AGENCY; HPA; HSBA; IMD; INVASIVE MENINGOCOCCAL DISEASE; MATS; MENB; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; MLST; MULTILOCUS SEQUENCE TYPING; NADA; NEISSERIA MENINGITIDIS SEROGROUP B; NEISSERIAL ADHESIN A; NEISSERIAL HEPARIN BINDING ANTIGEN; NHBA; OMV; OUTER MEMBRANE VESICLE; PBT; PORA; PORIN A; POSITIVE BACTERICIDAL THRESHOLD; RELATIVE POTENCY; RP; SBA; SEQUENCE TYPE; SERUM BACTERICIDAL ANTIBODY; SERUM BACTERICIDAL ANTIBODY ASSAY; SERUM BACTERICIDAL ANTIBODY ASSAY WITH HUMAN COMPLEMENT; ST; STRATIFIED PROPORTIONAL SAMPLING; TN; TP; TRUE NEGATIVES; TRUE POSITIVES;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PREDICTIVE VALUE OF TESTS; SERUM BACTERICIDAL ANTIBODY ASSAY; VACCINATION; WALES;

EID: 84885188791     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.006     Document Type: Article

References (33)

1. Rosenstein N.E., Fischer M., Tappero J.W. Meningococcal vaccines. Infectious Disease Clinics of North America 2001, 15(1):155-169.
2. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
3. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
4. European Medicines Agency. Bexsero. Available at: [accessed 11.03.13]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002333/human_med_001614.jsp%26mid=WC0b01ac058001d124.
5. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Molecular Microbiology 2005, 55:687-698.
6. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. Journal of Experimental Medicine 2002, 195:1445-1454.
7. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3770-3775.
8. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. Journal of Experimental Medicine 2003, 197:789-799.
9. Seib K.L., Serruto D., Oriente F., Delany I., Adu-Bobie J., Veggi D., et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infection and Immunity 2009, 77:292-299.
10. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
11. Wedege E., Bolstad K., Aase A., Herstad T.K., McCallum L., Rosenqvist E., et al. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clinical and vaccine immunology: CVI 2007, 14:830-838.
12. Borrow R., Miller E. Surrogates of protection. Handbook of meningococcal disease 2006, 323-351. Wiley-VCH, Weinheim. M. Frosch, M. Maiden (Eds.).
13. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus II. Development of natural immunity. Journal of Experimental Medicine 1969, 129:1327-1348.
14. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus I. The role of humoral antibodies. Journal of Experimental Medicine 1969, 129:1307-1326.
15. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proceedings of the National Academy of Sciences of the United States America 2010, 107:19490-19495.
16. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proceedings of the National Academy of Sciences of the United States America 1998, 95:3140-3145.
17. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases 2013, 13:416-425.
18. Cochran W.G. Sampling techniques 1977, John Wiley & Sons, Inc., New York (USA). 3rd ed.
19. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
20. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA-Journal of the American Medical Association 2012, 307:573-582.
21. Borrow R., Aaberge I.S., Santos G.F., Eudey T.L., Oster P., Glennie A., et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clinical and Diagnostic Laboratory Immunology 2005, 12:970-976.
22. Ott L., Longnecker M. An introduction to statistical methods and data analysis 2010, Brooks/Cole Cengage Learning, Australia, United States. 6th ed.
23. Altman D.G., Bland J.M. Diagnostic tests 2: predictive values. British Medical Journal 1994, 309:102.
24. Liddell D. Practical tests of 2×2 contingency tables. Journal of the Royal Statistical Society Series D (The Statistician) 1976, 25:295-304.
25. Snape M.D., Medini D., Halperin S.A., Detora L., Drori J., Moxon E.R. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30:B67-B72.
26. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatric Infectious Disease Journal 2012, 32:e20-e25.
27. Tzanakaki G., Kesanopoulos K., Xirogianni A., Hong E., Comanducci M., Comandi S., et al. Retrospective analysis of Meningococcal Antigen Typing System (MATS) on serogroup B meningococcal isolates in Greece. XVIIIth international pathogenic neisseria conference 2012.
28. Abad R., Luca O., Fabio R., Boccadifuocuo G., Comanducci M., Muzzi A., et al. Strain coverage of a meningococcal mulitcomponent (4CMenB) vaccine in Spain. XVIIIth international pathogenic Neisseria conference 2012.
29. Nissen M., Tozer S., Whiley D., Smith H., Rockett R., Jennison A., et al. Use of the Meningococcal Antigen Typing System (MATS) to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine. XVIIIth international pathogenic Neisseria conference 2012.
30. Kim E., Paulos S., Carlone G., Plikaytis B., Cohn A., Messonnier N., et al. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. XVIIIth international pathogenic Neisseria conference 2012.
31. Lemos A.P., Gorla M.C., Brandileone M.C., Orlandi L., Rigat F., Boccadifuoco G., et al. MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains. XVIIIth international pathogenic Neisseria conference 2012.
32. Claus H., Kriz P., Musilek M., Boccadifuoco G., Stella M., Frosi G., et al. Strain coverage of a multi-component meningococcus B vaccine in the Czech Republic and in Germany. XVIIIth international pathogenic Neisseria conference 2012.
33. Plikaytis B.D., Stella M., Boccadifuoco G., DeTora L.M., Agnusdei M., Santini L., et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clinical and Vaccine Immunology 2012, 19:1609-1617.